Chimeric antigen receptor and CAR-T cells that bind BCMA

US12048718B2 · kind B2 · utility

Assignee

• Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft · DE

Inventors

• Armin Rehm · Berlin, DE
• Uta Höpken · Berlin, DE
• Julia Bluhm · Berlin, DE
• Wolfgang Uckert · Berlin, DE
• Elisa Kieback · Berlin, DE
• Stephen Marino · Berlin, DE

Key dates

• Filing date: Jun 7, 2017
• Grant date: Jul 30, 2024
• Expiry date: Jul 21, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/03
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to an isolated chimeric antigen receptor polypeptide (CAR), wherein the CAR comprises an extracellular antigen-binding domain, comprising an antibody or antibody fragment that binds a B Cell Maturation Antigen (BCMA) polypeptide. The CAR preferably binds an epitope comprising one or more amino acids of residues 13 to 32 of the N-terminus of human BCMA. The invention further relates to a nucleic acid molecule encoding the CAR of the invention, a genetically modified immune cell, preferably a T cell, expressing the CAR of the invention and the use of said cell in the treatment of a medical disorder associated with the presence of pathogenic B cells, such as a disease of plasma cells, memory B cells and/or mature B cells, in particular multiple myeloma, non-Hodgkin's lymphoma or autoantibody-dependent autoimmune diseases.